Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sascha Pahernik

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Clinical Genitourinary Cancer|July 4, 2013
Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysisSabine Brookman-May, Matthias May, Shahrokh F Shariat, et al.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Scientific Reports|May 12, 2018
Genomic features of renal cell carcinoma with venous tumor thrombusGregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, et al.
European Urology|December 17, 2013
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
Scandinavian Journal of Urology|April 13, 2017
Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project)Matthias May, Cristian Surcel, Umberto Capitanio, et al.
Nature Communications|June 14, 2016
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneityRouven Hoefflin, Bernd Lahrmann, Gregor Warsow, et al.
The Journal of Urology|September 16, 2014
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
European Urology|August 19, 2015
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH StudyJames A Thomas, Andrea Tubaro, Neil Barber, et al.
European Urology|July 4, 2012
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)Sabine Brookman-May, Matthias May, Shahrokh F Shariat, et al.
Urologic Oncology|November 14, 2017
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)Derya Tilki, Thenappan Chandrasekar, Umberto Capitanio, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Clinical Genitourinary Cancer|July 4, 2013
Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysisSabine Brookman-May, Matthias May, Shahrokh F Shariat, et al.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Scientific Reports|May 12, 2018
Genomic features of renal cell carcinoma with venous tumor thrombusGregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, et al.
European Urology|December 17, 2013
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
Scandinavian Journal of Urology|April 13, 2017
Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project)Matthias May, Cristian Surcel, Umberto Capitanio, et al.
Nature Communications|June 14, 2016
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneityRouven Hoefflin, Bernd Lahrmann, Gregor Warsow, et al.
The Journal of Urology|September 16, 2014
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH studyAlexander Bachmann, Andrea Tubaro, Neil Barber, et al.
European Urology|August 19, 2015
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH StudyJames A Thomas, Andrea Tubaro, Neil Barber, et al.
European Urology|July 4, 2012
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)Sabine Brookman-May, Matthias May, Shahrokh F Shariat, et al.
Urologic Oncology|November 14, 2017
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)Derya Tilki, Thenappan Chandrasekar, Umberto Capitanio, et al.
Pageof 13